

## BIOGRAPHICAL SKETCH

NAME <b>Alisa S. Morris</b>	POSITION TITLE <b>Clinical Research Nurse</b> <b>Mary Bird Perkins - Our Lady of the Lake Cancer Center, Baton Rouge, LA</b>		
eRA COMMONS USER NAME (credential, e.g., agency login)			
EDUCATION/TRAINING <i>Registered Nurse</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	MM/YY	FIELD OF STUDY
Southeastern Louisiana University		01/1982- 12/1983	Education
Southeastern Louisiana University		01/1991 – 12/1992	Nursing
Our Lady of the Lake Nursing School	ADN	01/1993 – 12/1994	Nursing

### A. Personal Statement

As a Clinical Research Coordinator, I am responsible for the overall management of multiple clinical trials, from early phase to phase IV clinical trials, including, but not limited to multi-modality trials, treatment and cancer control studies with extensive experience in cooperative group trials. My experience in management and nursing has allowed me to contribute to my facility's high standard of health care delivery and ongoing research projects. My education and varied experiences in nursing and health care environment has allowed me to facilitate and coordinate individual activities required by clinical trials. In addition, it has allowed me to be better prepared to maintain compliance and follow individual guidelines related to clinical research and quality of care. I actively participate in daily screening and accrual of patients to NCI sponsored clinical trials. In addition, I provide vital information and input data into the NCCCP Screening and Accrual Log. I play a vital role as a CRC, by collaboration with various PIs, working with my clinical research team by reviewing and developing a familiarity with each protocol's requirements, meeting timelines, evaluation of the inclusion/exclusion criteria, screen, enroll and manage patients on medical oncology and radiation oncology clinical trials. I am responsible for the oversight of data management, coordination, preparation and participate to assist monitor/auditor visits, maintain required regulatory documentation and research drug inventory. My personal faith and characteristics contribute in my ability to give compassionate care to those patients and physicians who participate in clinical trials. I participate in bi-weekly tumor conferences which have enabled me to develop my knowledge base significantly. Also, I have volunteered in cancer awareness projects by promoting cancer awareness in my church and my community. I believe my experiences acquired as a professional and more importantly, as a research nurse, have prepared me to be an important member of the proposed NCORP program.

### B. Positions and Honors

1994-1996	Surgical/Urology/Charge Nurse, Our Lady of the Lake Regional Medical Center, Baton Rouge, LA
1996-May 2013	PACU/OR/SDC Nurse, Pre-Admit Nurse, Heart Cath Lab Nurse, Special Procedure and Endoscopy Nurse, Wound Care and Hyperbaric Nurse, Home Health Nurse, Case Manager, Quality Resource and Review Nurse, Patient Educator Nurse, Discharge Planner & Social Services Nurse, Labor and Delivery Nurse, Lane Regional Medical Center, Zachary, LA
2006-2012	PRN School Nurse, Livingston Parish School System, Livingston, LA

2013 Clinical Research Nurse, Mary Bird Perkins Our Lady of the Lake Cancer Center, Baton Rouge, LA

### **Professional and Memberships**

1995 Member, American Nursing Association  
2013 Member, Oncology Nursing Society and Baton Rouge Oncology Nursing Society

### **License and Certifications**

1994 - Present Registered Nurse, Louisiana State Board of Nursing  
1998 - Present Advanced Cardiac Life Support  
1999 Case Management Certification  
2001 Wound Care and Hyperbaric Certification  
2009 Patient Educator Certification  
2013 CITI Certification  
2013 IATA Certification

### **Other Experience and Professional Memberships and Honors**

Church Member	Bluff Creek Baptist Church
Board Member and Chairwoman	Louisiana Farm Bureau and Federation
Board Member and Vice President	Louisiana High School Rodeo Association
Board Member and Treasurer	East Feliciana Arts and Crafts Festival
Member and Child Advocate	Families Helping Families for Special Need Children

## **C. Selected Peer-reviewed Publications**

### **D. Research Support**

MBPCC-PS-1204 (Celldex) Olson (PI) 5/16/2012 -  
Vaccine therapy among newly diagnosed glioblastoma patients.  
The primary objective of the study is to confirm that the addition of rindopepimut/GM-CSF to adjuvant temozolomide improves overall survival in patients with newly diagnosed EGFRvIII positive glioblastoma who have undergone gross-total resection.

KLT\_PANC-001 Bienvenu (PI) 6/3/2013 -  
Advanced pancreatic cancer.  
The goal of this study is to compare the effect of gemcitabine + Kanglaite Injection (KLTi) to gemcitabine alone in patients with locally advanced or metastatic pancreatic cancer, not amenable to curative surgical resection.

PH3-01 (Present) Spell (PI) 12/20/2011 -  
Vaccine therapy in early stage HER2 low breast cancer.  
The primary objective is to compare the disease-free survival (DFS) in subjects with operable early-stage, node-positive breast cancer who receive standard of care multimodality therapy plus NeuVax with rhGM-CSF as the treatment group or standard of care multimodality therapy plus the placebo with the vaccine adjuvant, rhGM-CSF (sargramostim) as the control group.

NSABP B-43 Veith (PI) 12/19/2009 -  
HER2-Positive Ductal Carcinoma In Situ  
The primary aim of this trial is to determine whether trastuzumab given concurrently with radiation therapy is more beneficial in preventing subsequent ipsilateral breast cancer recurrence, ipsilateral skin cancer recurrence, or ipsilateral DCIS, when compared with radiation therapy alone in women with HER2-positive ductal carcinoma in situ (DCIS) resected by lumpectomy.

RTOG 1008 Veith (PI) 10/18/2011 -  
Malignant salivary gland tumors.

Acquire preliminary efficacy data comparing postoperative radiotherapy alone to concurrent chemotherapy and radiation using weekly cisplatin.

CALGB 80702                      Veith (PI)                      6/22/2010 -

Resected Stage III Colon Cancer.

To compare disease-free survival of patients with stage III colon cancer randomized to standard chemotherapy only (FOLFOX) or standard chemotherapy (FOLFOX) with 3 years of celecoxib 400 mg daily.

ECOG E3F05                      Veith (PI)                      2/9/2011 -

Symptomatic or progressive low grade gliomas.

To determine whether the addition of temozolomide to fractionated radiotherapy improves the progression-free survival (PFS) and median overall survival (OS) of patients requiring treatment for low-grade gliomas.

TALC                                  McWhorter (PI)                      7/28/2011 -

Laryngeal cancer observational study.

The immediate goals of this study are to compare the impact of primary chemoradiation versus surgery on patients with new tumors of the hypopharynx and cartilage-invading larynx) that would require total laryngectomy for cure.

TCGA (Total Cancer Genome Atlas Project)                      Vincent (PI)                      09/2013 -

Biospecimen procurement program.

The TCGA project is designed to try to identify all of the genetic changes that can cause cancer in people by studying the genetic and biochemical material from various types of cancer tissue collected.

Connect CLL                      Bienvenu (PI)                      4/27/2010 -

Chronic Lymphocytic Leukemia Disease Registry

Describe practice patterns of first-line therapy regimens and subsequent therapeutic strategies in patient initiated on therapy for CLL, as well as initiated on second line and subsequent therapies, in the community and academic setting.

### **Completed Research Support**

NCIC MA.32                      Veith (PI)                      11/10/2010 - 1/23/2013

Early stage breast cancer.

To compare invasive disease free survival (IDFS) between subjects treated with metformin (850 mg po bid for 5 years) versus placebo in addition to standard adjuvant therapy.

CCCWFU 98110                      Veith (PI)                      2/11/2011 - 11/18/2013

Erectile dysfunction.

To determine the "best dose" of ArginMax to be used in a subsequent Phase III trial.

NLG-0405                      Bienvenu (PI)                      5/11/2012 - 9/17/2013

Surgically resected pancreatic cancer.

To assess overall survival after treatment with a regimen of adjuvant therapy (gemcitabine alone or with 5-FU chemoradiation) with or without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in subjects who have undergone surgical resection.

DFCI (Young & Strong)                      Schmeckle (PI)                      10/25/2012 - 9/12/2013

Young women with breast cancer.

The overall objective of this study is to determine the effect of an education and support intervention for young women with breast cancer and their oncology providers (YWI) on attention to fertility issues compared to a physical activity comparison intervention (PAI) in a randomized controlled trial.

SWOG S0702

Veith (PI)

6/25/2013 - 12/13/2013

Incidence of osteonecrosis of the jaw in patients receiving Zometa.

The primary objective of this study is to prospectively assess the cumulative incidence of osteonecrosis of the jaw (ONJ) at 3 years in cancer patients with bone metastasis receiving zoledronic acid treatment.

MBPCC-PS 11-04 (Sciclone)

Bienvenu (PI)

7/25/2011 - 7/29/2013

The goal of this study is to evaluate the efficacy and safety of three different doses of SCV-07 in attenuating oral mucositis in patients with Head & Neck cancers receiving concurrent chemotherapy and radiotherapy